Skip to main content
. 2021 Oct 14;7(12):e214761. doi: 10.1001/jamaoncol.2021.4761

Figure 2. Mobocertinib Activity in Platinum-Pretreated Patients With EGFRex20ins Mutation–Positive Metastatic NSCLC (PPP Cohort).

Figure 2.

A, Best percentage change from baseline in the sum of the longest diameters of target lesions per independent review committee (IRC) assessment in patients who underwent follow-up imaging and could be evaluated for a response (101 patients). The solid line at −30% indicates the threshold for partial response according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. B, Objective response per IRC assessments by time on treatment in confirmed responders (n = 32). C, Kaplan-Meier–estimated duration of confirmed response per IRC assessments. D, Kaplan-Meier estimates of overall survival (OS). Of the 114 patients in the PPP cohort, 46 (40%) died. Tick marks in Kaplan-Meier plots indicate censored data.

ASV indicates V769_D770insASV; CR, complete response; EGFRex20ins, EGFR exon 20 insertion; NPH, H773_V774insNPH; SVD, D770_N771insSVD; NSCLC, non–small cell lung cancer; ORR, objective response rate; PD, progressive disease; PPP, platinum-pretreated patients; PR, partial response; SD, stable disease.

aSpecific EGFRex20ins mutations were identified by central tumor sequencing in 68 patients, reported by local test in 27 patients, insertion unknown in 16 patients, and unconfirmed in 3 patients.

bThe total number of patients in the table in panel A includes 13 patients with data not shown in the waterfall plot because they could not be evaluated for tumor response (2 with ASV/SVD/NPH mutations, 7 with other EGFRex20ins mutations, 3 with insertion unknown, and 1 with unconfirmed EGFRex20ins mutation).

cUnconfirmed complete response.